, that are each targets of T-and B-cell responses in approximately 10%-35% of LA patients. Although antibodies to these autoantigens may appear early in the infection, they seem to be nonpathogenic at this stage, with little or no associated T-cell responses. However, late in the disease, these autoantibodies are often accompanied by T-cell responses, particularly in patients with antibiotic-refractory LA, in whom they are associated with specific pathologic findings in joints [17] [18] [19] [20] 22] .
Control of the B. burgdorferi infection in humans is attributed predominantly to innate and adaptive T-helper 1 cell (T H 1) immune responses. However, excessive levels of inflammatory mediators, particularly those linked to T H 1 responses, are associated with more severe disease, including more symptomatic early infection and antibiotic-refractory LA [23] [24] [25] . Although initial studies in animals and humans suggest a role for T H 17 immunity in Lyme disease and in post-Lyme disease sequelae [26] [27] [28] [29] [30] , these responses are incompletely characterized, particularly in human disease.
We have previously analyzed innate and T H 1 adaptive immune responses in patients with early or late manifestations of Lyme disease and in tissue cell culture systems [23] [24] [25] [30] [31] [32] [33] . Here we extend this work by characterizing T H 17 immune responses in patients with Lyme disease. We found that a subset of patients have pronounced T H 17 responses, which are associated with B. burgdorferi antibodies during early infection in patients with EM, and with autoantibodies in patients with LA, a late disease manifestation.
PATIENTS AND METHODS

Study Patients
All patients met the Centers for Disease Control and Prevention criteria for the diagnosis of Lyme disease [34] and were treated according to the guidelines recommended by the Infectious Diseases Society of America [35] . All patients provided written informed consent. The Human Investigation Committees at Tufts Medical Center (1988) (1989) (1990) (1991) (1992) (1993) (1994) (1995) (1996) (1997) (1998) (1999) (2000) (2001) (2002) and Massachusetts General Hospital (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) (2015) (2016) approved the study.
For analysis of early infection, acute and convalescent serum samples and clinical information were available from 91 EM patients from the northeastern United States seen between 1998 and 2001, all of whom were culture positive for B. burgdorferi. In addition, serum and, in most instances, synovial fluid samples were available from 141 patients with LA who were referred to the Rheumatology Clinic at Tufts Medical Center or Massachusetts General Hospital from 1988 through 2014. These patients, were referred before, during, or after antibiotic treatment. For comparison, serum samples were obtained from 57 healthy laboratory and hospital donors. Although subsets of these samples were used in previous studies of innate and adaptive T H 1 responses [23] [24] [25] 32] , all of the samples were tested again here, along with new samples, so that variability between assays would not be a factor in data interpretation.
Laboratory Determinations
The levels of 21 cytokines and chemokines associated with innate (CCL2, CCL3, IL-1β, IL-6, IL-8, IL-10, tumor necrosis factor  [TNF], interferon [IFN] α) and adaptive T H 1 (IFN-γ, CXCL9,  CXCL10, IL-12p40, IL-12p70, CCL19) or T H 17 (IL-17A, IL-17F,  IL-17E/IL-25, IL-21, IL-22, IL-23, IL-27) immune responses were assessed in acute and convalescent serum samples from EM patients, in serum and synovial fluid samples from LA patients, and in serum of healthy subjects using Luminex multiplex assays (EMD Millipore). Because patient sample volumes were limited, cytokine and chemokine levels in these samples were determined once.
Antibody responses (immunoglobulin G [IgG] ) to B. burgdorferi, or to 3 human autoantigens specific for Lyme disease (ECGF, apoB-100, and MMP-10), were determined for this study in approximately 30-50 patients with EM or LA as previously described [17] [18] [19] [20] .
Statistical Analysis
Differences in cytokine and chemokine levels were assessed using Mann-Whitney rank-sum test. To show the range of values, differences among groups stratified according to EM-associated symptoms, or antibiotic-responsive vs antibiotic-refractory LA, were presented as box plots. Correlations involving inflammatory mediators and antibody responses were assessed using Pearson correlation test with BenjaminiHochberg correction for multiple comparisons. Analyses were performed using SigmaStat software (SPSS). A P value ≤.05 with false discovery rate (FDR) ≤0.1 was considered statistically significant.
RESULTS
Inflammatory Responses in Patients With Erythema Migrans
At study entry prior to antibiotic therapy, a median of 4 days after disease onset, the 91 B. burgdorferi culture-positive EM patients had significantly higher levels of 19 of the 21 mediators  tested, including all T H 17 mediators (IL-23, IL-27, IL-25, IL-22,  IL-17F, IL-21 , and IL-17A) compared with healthy subjects. Representative mediators of each type of immune response are shown in Figure 1A . During acute EM, most patients had robust innate and T H 1 adaptive immune responses, with especially high levels of CCL2, CXCL9, and CXCL10, which are important chemoattractants for macrophages and CD4 + T-effector cells.
Similarly, the levels of all T H 17 mediators assessed were greater in patients than in healthy subjects, although the values among patients were quite variable. Three weeks later, during the convalescent period, soon after the conclusion of antibiotic therapy, the levels of T H 1-associated mediators had decreased dramatically, and in some cases approached the levels in healthy subjects ( Figure 1A) . Similarly, the levels of most innate mediators had decreased significantly during convalescence. In contrast, the levels of T H 17 mediators declined less during convalescence, suggesting the potential for persistence of these responses after spirochetal killing [30] .
Of the 91 EM patients, 70 (77%) had at least one associated symptom, including fatigue, malaise, headache, fever, neck stiffness, arthralgias, chills, or myalgias. Patients with no symptoms had the lowest levels of inflammatory mediators; those with moderate symptoms (1-5 symptoms) had intermediate levels, and those with many symptoms (6-20 symptoms) had the highest levels ( Figure 1B ). The greatest differences among groups were observed for the T H 1-associated mediators IFN-γ, CXCL9, and CXCL10, and for the innate mediators IL-8, TNF, and IL-6. Similar trends were observed for T H 17 mediators, but these did not reach statistical significance. Thus, appropriate innate and adaptive immune responses appear important for control of the infection, but the consequence of excessive inflammation is more symptomatic early infection.
Inflammatory Responses in Patients With Lyme Arthritis
In patients with LA, which usually occurs months after initial spirochetal exposure, the disease was generally confined to one or a few large joints, particularly the knee. In these patients, the inflammatory responses, particularly innate and T H 1 responses, were concentrated in synovial fluid of the affected joints ( Figure 2A ). The levels of IFN-γ-inducible chemokines CXCL9 and CXCL10, which are potent chemoattractants for CD4
+ T H 1-effector cells, were often approximately 100-fold higher in synovial fluid compared with serum (P < .001). In addition, synovial fluid in LA patients contained very high levels of several innate immune mediators, including CCL2, IL-8, and IL-6. The levels of T H 17-associated mediators were also higher in LA patients compared with healthy subjects, but these responses were not uniformly concentrated in synovial fluid, suggesting that in some patients they may be occurring at extra-articular sites. Whereas the levels of IL-23, IL-27, and IL-17A were higher in synovial fluid compared with serum, the levels of IL-25, IL-22, and IL-17F were similar at both sites. When LA patients were subdivided into those with antibiotic-responsive arthritis or antibiotic-refractory arthritis, the refractory group had significantly higher synovial fluid levels of most innate-associated mediators, as well as higher levels of the T H 1-associated mediators CXCL9, CXCL10, and IFN-γ ( Figure 2B ). In contrast, the levels of T H 17 mediators in synovial fluid were similar in both the responsive and refractory groups. In serum, the generally low levels of innate and T H 1-associated mediators were similar in patients with responsive or refractory arthritis, although there was a trend toward higher levels of the T H 17-associated mediators IL-17F and IL-27 in the refractory group ( Figure 2B ). Thus, antibiotic-refractory LA was strongly associated with site-specific innate and T H 1-adaptive immune responses in joints, whereas there was a trend toward higher T H 17 responses in blood.
Borrelia Antibody Responses in Lyme Disease
To examine the associations between inflammatory mediators and antibody responses, the levels of innate, T H 1, and T H 17 mediators were correlated with B. burgdorferi-specific antibodies in 29 EM patients and 79 LA patients in whom sufficient sample volumes remained. Because no significant differences were observed in patients with refractory or responsive arthritis, these groups were combined for presentation here.
Early in the disease in EM patients, serum levels of one innate mediator (TNF), 4 T H 1 mediators (CXCL9, CXCL10, IL-12p40, and CCL19), and 4 T H 17 mediators (IL-17F, IL-23, IL-25, and IL-27) correlated directly with B. burgdorferi antibody levels ( Table 1 ). In contrast, late in the disease in LA patients, these correlations were minimal; only one Th17 mediator, IL-17F, correlated with Borrelia antibodies in serum, and there was a negative correlation with IL-8 and Borrelia antibodies in synovial fluid. Thus, early in the infection, when large numbers of spirochetes were present and the immune response was developing, high levels of innate, T H 1, and, in particular, T H 17 mediators correlated with high antibody responses to the spirochete. In contrast, late in the disease when immune responses were fully matured and the levels of inflammatory mediators were generally high, these correlations were no longer observed.
Antibody Responses to Lyme Disease-Associated Autoantigens
The levels of inflammatory mediators were then correlated with autoantibody levels to 3 Lyme disease-specific autoantigens (ECGF, apoB-100, and MMP-10) in serum of 23 EM patients or in synovial fluid of 42 LA patients in whom sufficient sample volume was still available. In serum from EM patients, ECGF autoantibodies correlated strongly with most innate mediators and with 2 T H 1 mediators, IFN-γ and IL-12p70 (Table 2) . Only one innate mediator (CCL2) and 3 T H 1 mediators (CXCL9, CXCL10, and CCL19) correlated with MMP-10 antibodies, and there were no correlations with apoB-100 autoantibodies. Moreover, early in the infection, there were no correlations between T H 17 mediators and autoantibodies in serum.
In contrast, in LA patients, when the protein levels of these autoantigens were typically very high in synovial fluid [17] [18] [19] , most T H 17 mediators, including IL-17F, IL-23, IL-25, and IL-27, correlated directly with autoantibody levels to each of the 3 autoantigens in synovial fluid (Table 2) . These correlations were not as pronounced in serum (data not shown). Moreover, when LA patients were stratified into antibiotic-responsive or antibiotic-refractory groups, IL-10, a prototypical anti-inflammatory cytokine, correlated with ECGF autoantibodies in patients with antibiotic-responsive LA. In contrast, T H 17 mediators correlated strongly with autoantibodies only in patients with antibiotic-refractory LA (Table 3) , suggesting a shift to an autoimmune phenotype in these patients. Thus, although innate and T H 1-associated cytokines were often high in synovial fluid in LA patients, it was T H 17 cytokine responses that correlated strongly with autoantibodies in patients with antibiotic-refractory LA, implicating T H 17 responses in maladaptive immune processes in these patients.
DISCUSSION
In this study, T H 17 inflammatory responses correlated with B. burgdorferi antibody levels early in the infection in EM patients, and with autoantibody levels to self-antigens late in the illness in patients with antibiotic-refractory LA. The protective or pathogenic effector functions of T H 17 cells are shaped by the composition of the local inflammatory milieu and the duration of exposure to such an environment. For example, transforming growth factor β and IL-6 appear to be essential for early T H 17 lineage determination [1] [2] [3] [4] . Such cells and their associated cytokines provide robust protection against extracellular pathogens, particularly bacteria and fungi, by rapid recruitment and activation of myeloid cells [1] [2] [3] . In contrast, prolonged or dysregulated exposure to IL-23 and IL-1β results in highly inflammatory T H 17 cells, which recruit and activate myeloid cells with capacity to cause autoimmunity and severe local tissue pathology [2] . Moreover, IL-23-induced T H 17 cells act directly on B cells and contribute to the generation of pathogenic autoantibodies that lead to onset of clinical inflammatory arthritis [36] . Studies in IL-23-deficient animals and in humans with IL-23R polymorphisms demonstrate that IL-23 is indispensible for the development of pathogenic T H 17 cells that lead to chronic tissue injury and autoimmunity [1, 2, [5] [6] [7] [8] . In human Lyme disease, which occurs in stages, one may observe both types of T H 17 responses at different stages of the disease.
During early infection, the abundance of B. burgdorferi antigens in EM skin lesions leads to increased levels of innate, T H 1, and T H 17-associated inflammatory mediators that appear to help control the infection. Additionally, the infection triggers antibody responses to B. burgdorferi, and in some patients, nonpathogenic autoantibodies develop [17] [18] [19] [20] , presumably due to polyclonal activation of B cells [37, 38] , or to close interactions between spirochetal and host lipids or proteins [39] . The fact that the 3 autoantigens studied here do not have sequence similarity with Borrelia proteins speaks against the T-cell epitope mimicry hypothesis [17] [18] [19] . Although some EM patients have pronounced T H 17 responses with particularly high levels of IL-23, the responses at this stage appear to be protective and correlate directly with the levels of B. burgdorferi antibodies but not with autoantibodies. In contrast with innate and T H 1 mediators, which decline markedly during convalescence, T H 17 mediators decline more slowly, and this proclivity to remain elevated may become disadvantageous. In a prospective study of European patients with EM, high IL-23 levels sometimes persisted for many months after antibiotic therapy and were associated with post-Lyme symptoms and ECGF autoantibodies [30] . These responses appear to change in LA patients, particularly in those with refractory LA, presumably due to differences in the local inflammatory environment and a shift toward high levels of self-antigens associated with immune processes in joints. Patients with antibiotic-refractory LA have exceptionally high levels of IL-6 in synovial fluid (~15 000 pg/mL vs ~10 pg/mL in EM sera), which is essential for T H 17 lineage specification. In addition, most patients have elevated levels of IL-23, which would presumably polarize T H 17 cells toward a pathogenic phenotype over the prolonged course of the disease, leading to recruitment of inflammatory myeloid cells that can induce local tissue injury [2, 3] . Moreover, emerging evidence demonstrates that IL-23-activated T H 17 cells control the inflammatory activity of autoantibodies by regulating their glycosylation state on newly differentiating plasmablasts, thereby contributing to the shift from asymptomatic to clinical onset of autoimmune arthritis [36] . These findings demonstrate a unique linkage between T H 17 immunity and pathogenic autoantibody responses, which appears to be absent with other mediators such as CCL19, CXCL9, and CXCL10, which have also been implicated in dysregulated immune responses after EM [40] or LA [23] [24] [25] . Thus, in some patients, the prolonged exposure to a chronic inflammatory environment, particularly high levels of IL-23, and the predominance of autoantigens in joints likely facilitates T H 17-associated autoimmune responses. As evidenced by recent work in rheumatoid arthritis, a prototypic chronic inflammatory arthritide, T H 17 immunity, in the context of IL-23 stimulation, not only sets the stage for autoimmune responses, but also contributes to affinity maturation and posttranslational modifications of autoantibodies, both of which are necessary for pathogenicity and clinically evidenced autoimmune disease in joints [36] . We postulate that a similar scenario may occur in patients with Lyme disease, in whom autoantibodies may be present during several stages of disease but appear to become pathogenic primarily in the subgroup of patients with antibiotic-refractory LA. The correlation of autoantibody responses with elevated IL-10 levels in patients with antibiotic-responsive LA suggests that these patients have the ability to control autoreactive responses and their immune system regains homeostasis following the resolution of the infection. In contrast, in patients with antibiotic-refractory LA, the combination of genetic predisposition, abundance of autoantigens in joints, and prolonged exposure to high levels of T H 17 mediators such as IL-23 leads to a shift toward immunoreactive autoantibody responses with pathogenic potential and persistent proliferative synovitis for months to years after antibiotic therapy.
Although an animal model of antibiotic-refractory LA is lacking, a unique mouse model supports a role for T H 17 immune responses in severe Lyme arthritis. C57/BL/6 mice vaccinated with formalin-inactivated B. burgdorferi, followed 3 weeks later by infection with live spirochetes, developed severe destructive arthritis [26, 28, 29] . This manipulation appears to lead to the development of pathogenic T H 17 cells, as the administration of neutralizing antibodies against IL-17 or IL-23 delayed the onset of joint swelling and ameliorated the histological changes associated with destructive arthritis. This was accompanied by a decrease in CD4 + IL-17-producing cells and an increase in CD4 + CD25 + T cells, presumably of a regulatory phenotype [29] .
In summary, our findings demonstrate that T H 17 responses span the clinical spectrum of Lyme disease from host defense against the causative pathogen during early infection to autoimmunity late in the disease in patients with antibiotic-refractory LA. It will be important to learn whether similar dysregulated immune responses may play a role in other manifestations of Lyme disease or post-Lyme phenomena. 
